RNASEH2B
Basic information
Region (hg38): 13:50909747-51024120
Previous symbols: [ "DLEU8", "AGS2" ]
Links
Phenotypes
GenCC
Source:
- Aicardi-Goutieres syndrome 2 (Definitive), mode of inheritance: AR
- Aicardi-Goutieres syndrome 2 (Strong), mode of inheritance: AR
- Aicardi-Goutieres syndrome (Supportive), mode of inheritance: AD
- Aicardi-Goutieres syndrome 2 (Definitive), mode of inheritance: AR
- prostate cancer (Limited), mode of inheritance: AD
- Aicardi-Goutieres syndrome 2 (Strong), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Aicardi-Goutieres syndrome 2 | AR | General | Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing | Cardiovascular; Gastrointestinal; Dermatologic; Hematologic; Neurologic | 9706629; 16845400; 20301648; 25243380 |
ClinVar
This is a list of variants' phenotypes submitted to
- Aicardi-Goutieres syndrome 2 (17 variants)
- Aicardi Goutieres syndrome (2 variants)
- not provided (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the RNASEH2B gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 89 | 90 | ||||
missense | 131 | 141 | ||||
nonsense | 9 | |||||
start loss | 1 | |||||
frameshift | 18 | |||||
inframe indel | 3 | |||||
splice donor/acceptor (+/-2bp) | 14 | 15 | ||||
splice region | 2 | 14 | 25 | 3 | 44 | |
non coding | 20 | 109 | 10 | 141 | ||
Total | 19 | 23 | 162 | 202 | 12 |
Highest pathogenic variant AF is 0.0000197
Variants in RNASEH2B
This is a list of pathogenic ClinVar variants found in the RNASEH2B region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
13-50909764-C-G | Aicardi Goutieres syndrome | Uncertain significance (Jun 14, 2016) | ||
13-50909783-C-T | Aicardi-Goutieres syndrome 2 | Uncertain significance (Jan 13, 2018) | ||
13-50909784-A-G | Aicardi-Goutieres syndrome 2 | Uncertain significance (Mar 02, 2018) | ||
13-50909849-C-A | Aicardi-Goutieres syndrome 2 | Uncertain significance (Jan 13, 2018) | ||
13-50909867-G-C | Aicardi-Goutieres syndrome 2 | Benign/Likely benign (Apr 29, 2021) | ||
13-50909896-G-A | Aicardi-Goutieres syndrome 2 | Uncertain significance (Jan 13, 2018) | ||
13-50909932-G-A | Aicardi-Goutieres syndrome 2 | Uncertain significance (Jan 12, 2018) | ||
13-50909960-C-G | Aicardi-Goutieres syndrome 2 | Likely benign (Jan 13, 2018) | ||
13-50909965-C-T | Aicardi-Goutieres syndrome 2 | Likely benign (May 26, 2021) | ||
13-50909970-G-A | Aicardi-Goutieres syndrome 2 | Uncertain significance (Jan 12, 2018) | ||
13-50910073-CGGCATG-C | Aicardi-Goutieres syndrome 2 | Uncertain significance (Oct 14, 2021) | ||
13-50910078-T-C | Aicardi-Goutieres syndrome 2 | Conflicting classifications of pathogenicity (Sep 01, 2021) | ||
13-50910078-TG-T | Aicardi-Goutieres syndrome 2 | Pathogenic (Aug 31, 2022) | ||
13-50910079-G-A | Pathogenic (May 16, 2016) | |||
13-50910080-G-C | Aicardi-Goutieres syndrome 2 | Uncertain significance (Oct 25, 2022) | ||
13-50910082-C-G | Aicardi-Goutieres syndrome 2 | Likely benign (Aug 16, 2023) | ||
13-50910085-T-G | Aicardi-Goutieres syndrome 2 | Likely benign (Jun 20, 2023) | ||
13-50910088-C-G | Aicardi-Goutieres syndrome 2 | Likely benign (Mar 09, 2023) | ||
13-50910091-G-T | Aicardi-Goutieres syndrome 2 | Likely benign (Oct 13, 2023) | ||
13-50910092-G-T | Aicardi-Goutieres syndrome 2 | Uncertain significance (Apr 21, 2022) | ||
13-50910094-C-T | Aicardi-Goutieres syndrome 2 • RNASEH2B-related disorder | Conflicting classifications of pathogenicity (Jan 19, 2023) | ||
13-50910096-G-A | Aicardi-Goutieres syndrome 2 | Uncertain significance (Aug 23, 2022) | ||
13-50910097-C-T | Aicardi-Goutieres syndrome 2 | Likely benign (Aug 09, 2023) | ||
13-50910101-G-A | Aicardi-Goutieres syndrome 2 | Uncertain significance (Aug 10, 2023) | ||
13-50910101-G-C | Aicardi-Goutieres syndrome 2 | Uncertain significance (Sep 02, 2021) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
RNASEH2B | protein_coding | protein_coding | ENST00000336617 | 11 | 60779 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
3.26e-9 | 0.315 | 125708 | 0 | 40 | 125748 | 0.000159 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | -0.239 | 154 | 146 | 1.06 | 0.00000666 | 2039 |
Missense in Polyphen | 46 | 43.356 | 1.061 | 644 | ||
Synonymous | -0.228 | 53 | 50.9 | 1.04 | 0.00000231 | 545 |
Loss of Function | 0.760 | 15 | 18.5 | 0.810 | 7.76e-7 | 266 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000483 | 0.000483 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.000109 | 0.000109 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.000220 | 0.000202 |
Middle Eastern | 0.000109 | 0.000109 |
South Asian | 0.000131 | 0.000131 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Non catalytic subunit of RNase H2, an endonuclease that specifically degrades the RNA of RNA:DNA hybrids. Participates in DNA replication, possibly by mediating the removal of lagging- strand Okazaki fragment RNA primers during DNA replication. Mediates the excision of single ribonucleotides from DNA:RNA duplexes. {ECO:0000269|PubMed:16845400, ECO:0000269|PubMed:21177858}.;
- Pathway
- DNA replication - Homo sapiens (human)
(Consensus)
Intolerance Scores
- loftool
- 0.193
- rvis_EVS
- 0.04
- rvis_percentile_EVS
- 56.92
Haploinsufficiency Scores
- pHI
- 0.120
- hipred
- N
- hipred_score
- 0.239
- ghis
- 0.554
Essentials
- essential_gene_CRISPR
- E
- essential_gene_CRISPR2
- E
- essential_gene_gene_trap
- E
- gene_indispensability_pred
- N
- gene_indispensability_score
- 0.275
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Rnaseh2b
- Phenotype
- nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); immune system phenotype; embryo phenotype; liver/biliary system phenotype; hematopoietic system phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); endocrine/exocrine gland phenotype; homeostasis/metabolism phenotype; cellular phenotype; growth/size/body region phenotype;
Gene ontology
- Biological process
- in utero embryonic development;RNA catabolic process;ribonucleotide metabolic process;regulation of G2/M transition of mitotic cell cycle;negative regulation of gene expression;positive regulation of fibroblast proliferation;RNA phosphodiester bond hydrolysis, endonucleolytic;regulation of DNA damage checkpoint
- Cellular component
- nucleus;nucleoplasm;ribonuclease H2 complex
- Molecular function
- RNA-DNA hybrid ribonuclease activity